Despite the widespread popularity of GLP-1 medications in the U.S., nearly three in four diabetes patients stop treatment within a year. While most research focuses on claims data and discontinuation rates, the patient experience behind long-term adherence remains under-explored. To better understand this, Thrivable collected 3,500 open-ended audio responses from 591 people with type 1 and type 2 diabetes using GLP-1s. The findings revealed that patients often succeed despite the healthcare system, not because of it.